Report cover image

Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Share, Trends, & Industry Analysis Report By Service Type (In-House, Contract Outsourcing), By Synthesis Type, By Animal Type, By Therapeutic Category, By Country – Market Fore

Publisher Polaris Market Research & Consulting LLP
Published Sep 01, 2025
Length 125 Pages
SKU # PLRS20451514

Description

The europe veterinary active pharmaceutical ingredients manufacturing market size is expected to reach USD 3.84 billion by 2034, according to a new study by Polaris Market Research. The report “Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Share, Size, Trends, Industry Analysis Report By Service Type (In-House, Contract Outsourcing), By Synthesis Type, By Animal Type, By Therapeutic Category, By Country; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Veterinary active pharmaceutical ingredients (APIs) are the core, biologically active substances manufactured for use in animal medicines. The production of active pharmaceutical ingredients is essential in creating safe and effective veterinary products, ranging from livestock antibiotics and vaccines to parasiticides and pain management drugs for companion animals.

Europe is a key region in the manufacturing of veterinary active pharmaceutical ingredients (VAPIs), characterized by its stringent regulatory framework, advanced technological infrastructure, and strong focus on innovation. The region encompasses a wide range of APIs for companion animals and livestock, driven by a sophisticated and high focus on animal health.

Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report Highlights

In terms of service type, the in-house segment dominated the revenue share in 2024, as several established veterinary pharmaceutical companies in Europe continued to rely on their internal production capabilities to ensure quality consistency, regulatory compliance, and cost efficiency.

Based on synthesis type, the chemical-based API segment accounted for a major revenue share in 2024 due to its established synthesis processes, cost-effectiveness, and ability to address a wide range of animal health conditions, including parasitic infections and bacterial diseases.

In terms of animal type, the production animals segment held the largest revenue share in 2024 due to the region’s strong livestock sector.

Based on therapeutic category, the antiparasitics segment dominated the revenue share in 2024 due to rising livestock and companion animal ownership.

Germany accounted for the largest Europe veterinary active pharmaceutical ingredients manufacturing market share in 2024. This is attributed to its advanced pharmaceutical manufacturing base and an established veterinary healthcare infrastructure.

The market in the UK is expected to grow at a robust CAGR from 2025 to 2034, owing to growing focus on companion animal health and rising adoption of advanced formulations.

A few key market players include Bayer AG, Boehringer Ingelheim International GmbH, ECO Animal Health Group PLC, Elanco, EUROAPI, FIS – Fabbrica Italiana Sintetici, Kempex Holland BV, MSD Animal Health, Suanfarma, and Zoetis Inc.

Polaris Market Research has segmented the Europe veterinary active pharmaceutical ingredients manufacturing market report on the basis of service type, synthesis type, animal type, therapeutic category, and country:

By Service Type Outlook (Revenue, USD Billion, 2020–2034)

In House

Contract Outsourcing

Contract Development

Preclinical Development

Clinical Development

Contract Manufacturing

By Synthesis Type Mode Outlook (Revenue, USD Billion, 2020–2034)

Chemical-based API

Biological API

HPAPI

By Animal Type Outlook (Revenue, USD Billion, 2020–2034)

Production Animals

Companion Animals

By Therapeutic Category Outlook (Revenue, USD Billion, 2020–2034)

Antiparasitics

Anti-infectives

NSAIDs

Others

By Country Outlook (Revenue, USD Billion, 2020–2034)

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Table of Contents

125 Pages
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Source
3.2.1. Primary Source
3.2.2. Secondary Source
4. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Insights
4.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – Market Snapshot
4.2. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rising Expenditure on Animal Health
4.2.1.2. Increasing Investment in Facility Expansion
4.2.2. Restraints and Challenges
4.2.2.1. Stringent Regulation
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Trends
4.6. Value Chain Analysis
5. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type
5.1. Key Findings
5.2. Introduction
5.2.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
5.3. In-House
5.3.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by In-House, by Region, 2020-2034 (USD Billion)
5.4. Contract Outsourcing
5.4.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Contract Outsourcing, by Region, 2020-2034 (USD Billion)
5.4.2. Contract Development
5.4.2.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Contract Development, by Region, 2020-2034 (USD Billion)
5.4.2.2. Preclinical Development
5.4.2.2.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Preclinical Development, by Region, 2020-2034 (USD Billion)
5.4.2.3. Clinical Development
5.4.2.3.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Clinical Development, by Region, 2020-2034 (USD Billion)
5.4.3. Contract Manufacturing
5.4.3.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Contract Manufacturing, by Region, 2020-2034 (USD Billion)
6. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type
6.1. Key Findings
6.2. Introduction
6.2.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
6.3. Chemical-based API
6.3.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Chemical-based API, by Region, 2020-2034 (USD Billion)
6.4. Biological API
6.4.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Biological API, by Region, 2020-2034 (USD Billion)
6.5. HPAPI
6.5.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by HPAPI, by Region, 2020-2034 (USD Billion)
7. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type
7.1. Key Findings
7.2. Introduction
7.2.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
7.3. Production Animals
7.3.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Production Animals, by Region, 2020-2034 (USD Billion)
7.4. Companion Animals
7.4.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Companion Animals, by Region, 2020-2034 (USD Billion)
8. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category
8.1. Key Findings
8.2. Introduction
8.2.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
8.3. Antiparasitics
8.3.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Antiparasitics, by Region, 2020-2034 (USD Billion)
8.4. Anti-infectives
8.4.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Anti-infectives, by Region, 2020-2034 (USD Billion)
8.5. NSAIDs
8.5.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by NSAIDs, by Region, 2020-2034 (USD Billion)
8.6. Others
8.6.1. U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Alivira Animal Health Limited
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Bimeda Inc.
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Excel Industries Limited
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Elanco Animal Health
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. FIS - Fabbrica Italiana Sintetici S.p.A.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Huateng Pharma
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Huvepharma AD
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Merck Animal Health
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Ofichem Group B.V.
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Phibro Animal Health Corporation
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. Rochem International Inc.
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
10.12. SUANFARMA S.A
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Recent Development
10.13. Zoetis Inc.
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. Product Benchmarking
10.13.4. Recent Development

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us